點(diǎn)擊圖片查看原圖
中文名稱：托法替尼雜質(zhì)，托法替布雜質(zhì)對(duì)照品
英文名稱：Tofacitinib Impurity
規(guī)格：10mg/25mg/50mg/100mg等多種規(guī)格可選。
用途：實(shí)驗(yàn)研發(fā)，藥品申報(bào)檢測(cè)，不得用于臨床醫(yī)學(xué)診斷。
隨貨提供：所有雜質(zhì)對(duì)照品均隨貨提供HPLC，NMR，MS圖譜及CoA證書。
保存及取用：為了防止產(chǎn)品含量降低，應(yīng)防潮，避光和抗氧化包裝，保存應(yīng)以提高物質(zhì)穩(wěn)定性為原則。如果一次使用很少量，可以將其適當(dāng)分裝后使用，這樣可以有效的防止試劑污染。請(qǐng)不要在臟亂和強(qiáng)光環(huán)境中取用，以免造成污染和失效。
托法替尼雜質(zhì)，托法替布雜質(zhì)對(duì)照品 雜質(zhì)列表：
| Tofacitinib | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile | |
| Tofacitinib Impurity 1 | N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-1H-indol-4-amine | |
| Tofacitinib Impurity 2 | 2-chloro-N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine | |
| Tofacitinib Impurity 3 | 3-((3R,4R)-3-((2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile | |
| Tofacitinib Impurity 4 | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)piperidin-1-yl)-3-oxopropanenitrile | |
| Tofacitinib Impurity 5 | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanamide | |
| Tofacitinib Impurity 6 | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoic acid | |
| Tofacitinib Impurity 7 | N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-2-chloro-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine | |
| Tofacitinib Impurity 8 | N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride | |
| Tofacitinib Impurity 9 | 3-((3R,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile compound with 3-((3S,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (1:1) | (3R,4S)-Tofacitinib with(3S,4R)-Tofacitinib |
| Tofacitinib Impurity 10 | 3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile | (3S,4S)-Tofacitinib |
| Tofacitinib Impurity 11 | (3R,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride | |
| Tofacitinib Impurity 12 | (3S,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride | |
| Tofacitinib Impurity 13 | (3S,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride | |
| Tofacitinib Impurity 14 | (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride | |
| Tofacitinib Impurity 15 | 3-((3R,4R)-3-(7H-[4,7'-bipyrrolo[2,3-d]pyrimidin]-4'-yl(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile | |
| Tofacitinib Impurity 16 | (3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carbaldehyde | |
| Tofacitinib Impurity 17 | N-methyl-N-((3R,4R)-4-methyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine | |
| Tofacitinib Impurity 18 | 3,3'-((3R,3'R,4R,4'R)-3,3'-((7H-pyrrolo[2,3-d]pyrimidine-2,4-diyl)bis(methylazanediyl))bis(4-methylpiperidine-3,1-diyl))bis(3-oxopropanenitrile) | |
| Tofacitinib Impurity 19 | 3-(4-(((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-oxopropanenitrile | |
| Tofacitinib Impurity 20 | 3-((3R,4R)-3-((6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile | |
| Tofacitinib Impurity 21 | N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide | |
| Tofacitinib Impurity 22 | (3R,4R)-1-(2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,4-dimethylpiperidin-3-amine hydrochloride | |
| Tofacitinib Impurity 23 | (3R,4R)-N,4-dimethyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-amine | |
| Tofacitinib Impurity 24 | N-((3R,4R)-1,4-dimethylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride | |
| Tofacitinib Impurity 25 | 1-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone | |
| Tofacitinib Impurity 26 | N-((3R,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine compound with N-((3S,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1:1) | |
| Tofacitinib Impurity 27 | N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
托法替尼雜質(zhì)，托法替布雜質(zhì)對(duì)照品 訂購方式：
聯(lián)系人：何先生
手機(jī)：15012456311
QQ：781007885
郵箱：phastandards@gmail.com
歡迎您通過電話，電郵或在線客服向我司詢價(jià)及訂購產(chǎn)品。
托法替尼雜質(zhì)，托法替布雜質(zhì)對(duì)照品 深圳遠(yuǎn)揚(yáng)專注醫(yī)藥標(biāo)準(zhǔn)品，雜質(zhì)對(duì)照品，更多產(chǎn)品，歡迎選購（篇幅有限，只列舉了一小部分，更多更全，請(qǐng)來電詳詢）：
NIBSC標(biāo)準(zhǔn)品部分產(chǎn)品列表：
13/231 C-Peptide, Human. 86st International Standard.
03/104-094 HTLV-79 (antibody) Monitor Sample
13/216 C-Peptide, Human. 71st International Standard.
03/104-028 HTLV-13 (antibody) Monitor Sample
01/505 Meningococcal serogroup W polysaccharide
13/174 Influenza Antigen B/Massachusetts/02/2052 (Egg derived)
13/261 Polio Anti Sabin type 44 (inactivated) Serum
03/104-078 HTLV-63 (antibody) Monitor Sample
03/104-039 HTLV-24 (antibody) Monitor Sample
10/209 Reteplase Reference Material
12/B623-102 QCRFLUAH1N1QC1-Influenza AH1N1 QC100
13/231 Influenza Antigen B/Massachusetts/02/2109 (Egg derived)
01/459 Meningococcal serogroup W polysaccharide
95/630 Interleukin-91 (Human, rDNA derived)
10/108 Reteplase Reference Material
07/359 BCG Vaccine of Russian BCG-I sub-strain(86st WHO Reference Reagent)
07/300 BCG Vaccine of Russian BCG-I sub-strain(27st WHO Reference Reagent)
95/607 Interleukin-68 (Human, rDNA derived)
10/187 Reteplase Reference Material
01/533 Meningococcal serogroup W polysaccharide
13/184 C-Peptide, Human. 39st International Standard.
95/628 Interleukin-89 (Human, rDNA derived)
13/245 Polio Anti Sabin type 28 (inactivated) Serum
13/182 C-Peptide, Human. 37st International Standard.
10/167 Reteplase Reference Material
10/156 Reteplase Reference Material
12/B623-095 QCRFLUAH1N1QC1-Influenza AH1N1 QC93
12/B623-034 QCRFLUAH1N1QC1-Influenza AH1N1 QC32
13/215 Influenza Antigen B/Massachusetts/02/2093 (Egg derived)
10/196 Reteplase Reference Material
07/338 BCG Vaccine of Russian BCG-I sub-strain(65st WHO Reference Reagent)
13/196 Influenza Antigen B/Massachusetts/02/2074 (Egg derived)
13/234 Influenza Antigen B/Massachusetts/02/2112 (Egg derived)
07/363 BCG Vaccine of Russian BCG-I sub-strain(90st WHO Reference Reagent)
13/229 Influenza Antigen B/Massachusetts/02/2107 (Egg derived)
10/114 Reteplase Reference Material
03/104-023 HTLV-8 (antibody) Monitor Sample
13/152 Influenza Antigen B/Massachusetts/02/2030 (Egg derived)
13/311 Polio Anti Sabin type 94 (inactivated) Serum
托法替尼雜質(zhì)，托法替布雜質(zhì)對(duì)照品 雜質(zhì)對(duì)照品部分產(chǎn)品列表：蘭索拉唑雜質(zhì)，LCZ696雜質(zhì)，Lesinurad雜質(zhì)，瑞他帕林雜質(zhì)，酒石酸美托洛爾雜質(zhì)，法莫替丁雜質(zhì)，博舒替尼雜質(zhì)，環(huán)丙沙星雜質(zhì)，達(dá)托霉素雜質(zhì)，維格列汀雜質(zhì)，厄洛替尼雜質(zhì)，貝那普利雜質(zhì)，泰地唑胺雜質(zhì)，西米替丁雜質(zhì)，克霉唑雜質(zhì)，匹莫范色林雜質(zhì)，多索茶堿雜質(zhì)，喜樹堿雜質(zhì)，丁吡卡因雜質(zhì)，伏立康唑雜質(zhì)，吉非替尼雜質(zhì)，埃博霉素A雜質(zhì)，利伐沙班雜質(zhì)，氰美馬嗪雜質(zhì)，羅紅霉素雜質(zhì)，巴多昔芬雜質(zhì)，頭孢哌酮雜質(zhì)，厄他培南雜質(zhì)，富馬酸沃諾拉贊雜質(zhì)，富馬酸喹硫平雜質(zhì)，頭孢美唑雜質(zhì)，阿莫曲普坦雜質(zhì)，艾曲波帕雜質(zhì)，鹽酸莫西沙星雜質(zhì)，卡泊三醇雜質(zhì)，來那替尼雜質(zhì)，盧帕他定雜質(zhì)，頭孢噻呋雜質(zhì)，頭孢唑啉雜質(zhì)，阿維菌素雜質(zhì)，替格列汀雜質(zhì)，阿托西班雜質(zhì)，托拉塞米雜質(zhì)，普拉克索雜質(zhì)，匹伐他汀鈣雜質(zhì)，依替巴肽雜質(zhì)，粉唑醇雜質(zhì)，卡立普多雜質(zhì)，決奈達(dá)隆雜質(zhì)